Sage Journals: Discover world-class research

Open access

Review article

First published 2017

CDK4/6 Inhibitors in Cancer Therapy: A Novel Treatement Strategy for Bladder Cancer

Qi Pan, Anuja Sathe, Peter C. Black [...]

Bladder Cancer

Open access

Review article

First published 2023

CDK4/6 inhibitors: basics,pros,and major cons in breast cancer treatment with specific regard to cardiotoxicity – a narrative review

Dragica Pavlovic, Danijela Niciforovic, Dragana Papic [...]

Therapeutic Advances in Medical Oncology

Retricted access

Review article

First published 2024-4

Cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer

John P Micha, Mark A Rettenmaier, Randy D Bohart [...]

Journal of Oncology Pharmacy Practice

Open access

Editorial

First published 2018

Managing advanced HR-positive,HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?

Lorenzo Rossi, Amelia McCartney, Emanuela Risi [...]

Therapeutic Advances in Medical Oncology

Open access

Review article

First published 2019

The emerging role of CDK4/6i in HER2-positive breast cancer

Ciara C. O’Sullivan, Vera J. Suman, Matthew P. Goetz

Therapeutic Advances in Medical Oncology

Open access

Review article

First published 2024

Advances in the mechanism of CDK4/6 inhibitor resistance in HR+/HER2− breast cancer

Sijia Wu, Junnan Xu, Yiwen Ma [...]

Therapeutic Advances in Medical Oncology

Open access

Research article

First published 2023

Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors

Emma Zattarin, Luigi Mariani, Alice Menichetti [...]

Therapeutic Advances in Medical Oncology

Open access

Research article

First published 2024

Real-world comparison of palbociclib,abemaciclib,and dalpiciclib as first-line treatments for Chinese HR+/HER2−metastatic breast cancer patients: a multicenter study (YOUNGBC-28)

Yifan Chen, Yizhao Xie, Die Sang [...]

Therapeutic Advances in Medical Oncology

Retricted access

Review article

First published 2024-6

Adjuvant treatment in hormone receptor-positive early breast cancer: New approaches of endocrine therapy

Simone Nardin, Tommaso Ruelle, Irene Giannubilo [...]

Tumori Journal

Open access

Research article

First published 2023

Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer

Dennis J. Slamon, Peter A. Fasching, Sara Hurvitz [...]

Therapeutic Advances in Medical Oncology

Search results